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Abstract
Background: Oxidized low-density lipoprotein (oxLDL) mediates the transformation of macrophages (MΦ) to
cholesterol-rich foam cells and the release of pro-inflammatory cytokines during atherogenesis. JAB1 (Jun activation
domain binding protein-1) is present in all stages of human plaques, involved in the Toll-like receptor-mediated
activation of p38 mitogen-activated protein kinase (MAPK) and controls nuclear factor-kappa B (NF-κB) activation.
Thus, we were interested in the role of JAB1 during foam cell formation of MΦ after oxLDL exposition.
Methods and results: We found that JAB1 was present in CD68-immunoreactive (−ir) MΦ in atherosclerotic
plaques of apolipoprotein E knockout (ApoE−/−) mice after a high cholesterol/fat diet. Furthermore, differentiated
human U937 MΦ - incubated with oxLDL (4 h) to induce foam cell formation – showed a significant increase of
JAB1 (50 μg/ml: 1.39 + 0.15-fold; 100 μg/ml: 1.80 + 0.26-fold; 200 μg/ml: 2.05 + 0.30-fold; p < 0.05) on the protein
level compared to the control. Independent from JAB1 silencing, we found an increase of total cholesterol (TC), free
cholesterol (FC) and cholesteryl ester (CE) after oxLDL exposition. However, siJAB1-MФ showed a reduction of
tumor necrosis factor-alpha (TNF-α) (36%; p < 0.05 vs. non-transfected MФ) and interleukin (IL)-6 (30%; p < 0.05 vs.
non-transfected MФ) mRNA expression, as well as TNF-α (46%; p < 0.05 vs. non-transfected MФ) and IL-6 (32%; p < 0.
05 vs. non-transfected MФ) protein secretion after oxLDL exposition. In parallel with an upregulation of
inflammatory cytokines (TNF-α, IL-6) after oxLDL exposition, we found a significant (p < 0.05) increase of 37% in p38
MAPK activation after 4 h oxLDL-treatment, independent from NF-kB signaling. In this context, we showed regional
co-localization of JAB1 with p38 MAPK in atherosclerotic plaques of ApoE−/− mice. Moreover, we detected
interaction of JAB1 with p38 MAPK in U937 cells.
Conclusion: We demonstrate that oxLDL induces JAB1 expression and influences its cellular localization, whereby
the p38 MAPK signaling pathway is modified with consequences for inflammation of human MΦ in foam cells and
atherosclerotic lesions.
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Background
Atherosclerosis is a chronic and inflammatory disease,
and it is well established that atherosclerotic lesions arise
from an enhancement of LDL uptake by monocytes and
macrophages (MΦ) [1]. The interaction of oxLDL and
MΦ is a hallmark in the development and progression of
atherosclerosis [2]. MΦ which internalized oxLDL via
scavenger receptors subsequently transform into lipid-
laden foam cells [3] and release various pro-inflammatory
cytokines such as tumor necrosis factor-alpha (TNF-α) -
under the transcription control of NF-κB - upon exposure
to oxLDL [4].
Thus, NF-κB is a key regulator of inflammation during
the atherosclerotic process. Under normal conditions,
Ik-Bα (nuclear factor of kappa light polypeptide gene en-
hancer in B-cells inhibitor, alpha) binds to NF-κB, a
complex which remains in the cytosol when inactive.
Various exogenous inflammatory signals lead to phos-
phorylation of Ik-Bα on the Ser32/Ser36 residues by
IkBkinaseß (IKKß). The phosphorylated Ik-Bα degrades
rapidly via the ubiquitin proteasome system (UPS) [5].
Thereby, NF-κB molecules can translocate into the
nucleus to allow gene transcription. NF-κB activation
controls the Ik-Bα expression with an auto-regulatory
negative feedback loop [6].
Equally, oxLDL activates the mitogen-activated protein
kinase (MAPK) signaling transduction pathway. Most re-
cent studies have shown that an inhibition of p38 MAPK
restrains the oxLDL-induced foam cell formation in
murine RAW264.7 cells [7]. The direct substrate of p38
MAPK is the MAPK-activated protein kinase-2 (MK2).
Deletion of the MK2 gene in mice resulted in an impaired
inflammatory response with reduced production of pro-
inflammatory mediators (TNF-α, IL-6) in response to a
challenge with lipopolysaccharide (LPS) [8, 9].
Furthermore, it was supposed that an increased
expression of JAB1 correlates with athero-progression
[10], because Constitutive photomorphogenesis 9 (COP9)
signalosome complex unit 5 (CSN5) was found in endo-
thelial cells and MΦ of human atherosclerotic lesions
[10–12] and is involved in the regulation of protein stabil-
ity and protein degradation [13–15]. Especially, JAB1 was
implicated in the ubiquitin-proteasome degradation ma-
chinery and the regulation of signal transduction pathways
[16]. In this context, the deneddylation activity was
pinpointed to the JAB1/MPN (Mpr/Pad1/N-terminal)
domain metalloenzyme (JAMM) submotif located in the
MPN domain of JAB1 [17]. Also, it was shown that JAB1
controls the Ik-Bα stability which regulates the activity of
SCF (Skp1, Cullins, F-box proteins)-type CRL (Cullin-
RING ubiquitin Ligase) by deneddylation [18, 19]. JAB1
silence induced Ik-Bα degradation, enhanced NF-κB
activity, increased the TNF-a-induced expression of
adhesion molecules (CCL2, ICAM-1, VCAM-1) and induced
monocytes arrest rate on inflamed endothelium in
vitro [10]. Furthermore, JAB1 is a critical factor to
trigger an appropriate innate immune response and is
required for activation of p38 MAPK [20]. Deng et al.
showed that JAB1 deletion in bone marrow-derived
MΦ from CSN5-deficient mice attenuated signifi-
cantly the TNF-α-mediated induction of p38 MAPK
phosphorylation and increased the expression of anti-
inflammatory genes [20].
The purpose of our investigation was to find out if
Jab1 expression is regulated by oxLDL as well as its
relation to the NF-kB transcription factor and the activa-




Male B6.apolipoprotein E knockout (ApoE−/−) B6.129P2-
Apotm1Unc/J mice (Charles River, Sulzfeld, Germany)
were used for experiments (n = 4). At an age of 10 weeks,
the offspring was fed with an adjusted-calories
cholesterol-enriched diet (CED, TD.88137; Harlan Teklad,
Madison, WI) for a period of 20 weeks. The brachiocepha-
lic trunks were removed, shock-frozen in liquid nitro
gen–cooled isopentane and kept at −70 °C in a freezer
until used for immunohistochemical investigations [21].
All animal experiments were approved by the Regierung-
spräsidium Karlsruhe and the local authorities at the
Universitiy of Heidelberg (Az 35–9185.81/g-99/06).
Cell culture, transfection and gene silencing
The human leukemic monocyte lymphoma cell line
U937 (Cell line service, Eppelheim, Germany) was used.
Originally, the culture was derived from a histiocytic
lymphoma and is frequently used as a model of
monocyte/MΦ cell lineage [22, 23]. U937 cells were dif-
ferentiated into MΦ using 20nM Phorbol 12-mystriate
13-acetate [PMA, (Sigma-Aldrich Chemie GmbH
Munich, Germany)] in RPMI 1640 medium for 24 h.
Afterwards, MΦ were incubated with human oxLDL
(50–200 μg/ml) or LPS (0.1 μg/ml) for 4 h. Transfection
of U937 MФ with 50nM pre-designed JAB1 siRNA
(siJAB1-MФ) (FlexiTube GeneSolutionGS10987, QIA-
GEN GmbH, Hilden, Germany) and negative siRNA (nsi-
JAB1-MФ) (AllStars Negative Control, QIAGEN GmbH,
Hilden, Germany) was performed using HiPerfect Trans-
fection Reagent (QIAGEN GmbH, Hilden, Germany)
following the manufacturer’s instruction. Therefore, cells
incubated with “medium” containing HiPerfect Transfec-
tion Reagent was used as additional control. After
transfection, cells were allowed to recuperate for 48 h
before being treated with 50 μg/ml oxLDL (4 h). As
positive control, we used the AllStars Hs Cell Death Control
siRNA (QIAGEN GmbH, Hilden, Germany), a compound
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of highly potent siRNAs targeting ubiquitously expressed
human genes that are essential for cell survival. Transfection
efficiency was estimated by observing cells by light micros-
copy 48 h after transfection with the AllStars Hs Cell Death
Control siRNA.
SDS-PAGE and western blot
PMA-differentiated U937 MΦ were washed in ice-cold
phosphate buffered saline (PBS) and lysed using RIPA
(radioimmuniprecipitation assay) buffer pH 7.5 (Cell
Signaling Technology Europa, Leiden, The Netherlands),
containing protease/phosphatase inhibitor cocktail (Cell
Signaling Technology, Boston, USA). The protein con-
centrations were determined spectrophotometrically
using the Pierce BCA (bicinchoninic acid) Protein Assay
(Thermo Scientific, Rockford, USA). Proteins were
loaded on NuPAGE® Novex® 4–12% Bis-Tris Gels, pre-
cast polyacrylamide gels (Life Technologies GmbH,
Darmstadt Germany). Proteins were transferred onto
0.45 μm nitrocellulose membranes [Millipore (Billerica,
MA, USA)]. Primary Antibodies (see Additional file 1)
were added and incubated overnight at 4 °C in blocking
buffer (5% milk). Membranes were incubated with
enhanced ECL-anti-goat IgG-POD antibody, ECL-anti-
mouse IgG-POD antibody or ECL-anti-rabbit IgG-POD
antibody. The peroxidase reaction was visualized by Ace-
Glow chemiluminescence substrate (Peqlab, Erlangen,
Germany) and documented by the Fusion-SL Advance™
imaging system (Peqlab) according to the instruction
manual. The intensity of the specific western blot bands
was quantified using the software ImageJ from the
National Institutes of Health (Bethesda, USA).
LDL oxidation
LDL (Cell sciences, Canton, USA) oxidation was per-
formed as previously described by Galle and Wanner
[24] and Steinbrecher [25]. The LDL was resuspended in
endotoxin-free PBS (LONZA, Ratingen, Germany) to a
final concentration of 1 mg protein/ml and dialyzed
using Slide-A-Lyzer Dialysis Cassettes 7 K MWCO
(Thermo Fisher Scientific Inc., Rockford, USA). The grade
of oxidation was verified by spectrophotometric analysis
(absorbance spectrum between 400 and 600 nm). After
oxidative modification, the absorption peaks at at 460
and 485 nm, which are characteristic for native LDL,
disappear [24].
Viability assay
For analysis of cell survival, U937 (6.25*105 cells/ml)
cells were cultured in 96 well plates, differentiated into
MΦ as described above and treated with or without
oxLDL or LPS. Cell viability was assessed using Presto-
Blue™ [26], according to the manufacturer’s protocol. 1 h
after the addition of PrestoBlue™, the optical density
(OD) was measured at 570 nm and 600 nm (as refer-
ence) by a SUNRISE ELISA-reader (Tecan, Salzburg,
Austria). Results are presented in % survival = [Sample
OD(570nm - 600nm reference)*100)/Control OD(570nm - 600nm
reference)]. As control (=100% were cultured with medium
alone (i.e. without addition of test substances) [26].
OilRed O staining
The Oil Red O [ORO, (Sigma-Aldrich)] working solution
was prepared by diluting the stock solution (3 mg/ml
ORO dissolved in 2-propanol) with distilled water (3:2).
For staining, PMA differentiated U937 MΦ were fixed in
10% PFA, and the ORO working solution was added to
the culture dishes afterwards. The nuclei were stained
using Mayer’s hemalum solution (Carl Roth, Karlsruhe,
Germany).
Cholesterol/cholesteryl ester quantitation
For analyses of the TC and FC, U937 cells (106 cells/
well) were cultured in 6 well plates, differentiated into
MΦ as described above and incubated with or without
50 μg/ml oxLDL for 4 h. TC and FC were determined
using the Cholesterol/Cholesteryl Ester Quantitation
Assay (Abcam plc., Cambridge, UK), according to the
manufacturer’s protocol. The OD was measured at
570 nm by a SUNRISE ELISA-reader (Tecan, Salzburg,
Austria). TC and FC results are presented in μg/mg
protein (determined as described above). CE was deter-
mined by subtracting the value of FC from the TC.
Extraction of cytoplasmic and nuclear proteins
After treatment, PMA-differentiated U937 MΦ were
washed in ice-cold PBS and lysed by cytoplasmic extract
buffer (10 mol/ml HEPES (pH 7.9), 10 mol/ml KCl,
0.1 mol/ml EDTA, 0.3% NP-40) (Roth) in the presence
of protease/phosphatase inhibitor cocktail (Sigma
Aldrich) and centrifuged (1,500 x g; 5 min; 4 °C). The
supernatant containing the cytoplasmic fraction was
separated. The pellet was suspended in RIPA buffer and
centrifuged to obtain the supernatant containing the
nuclear fraction.
Co-immunoprecipitation assay
Protein interactions were verified for U937 MΦ by using
the Thermo Scientific™ Pierce™ Co-immunoprecipitation
(Co-IP) Kit (Thermo Fisher Scientific Inc., Rockford,
USA). The immunoprecipitation of the endogenous
protein occurred with JAB1 antibody-coupled resin. For
that, the cells were lysed with Lysis/Wash buffer supple-
mented with a protease/phosphatase inhibitor cocktail
(Sigma Aldrich) and centrifuged to pellet the cell debris.
1 mg of total protein from the supernatant was clarified
using the Control Agarose Resin Column (crosslinked
4% beaded agarose) to reduce nonspecific protein
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binding. The eluate of the Control Agarose Resin served
as negative control for unspecific protein binding to
resin, because the supplied Pierce Control Agarose Resin
is composed of the same support material as the Amino-
Link Plus™Coupling Resin, but was not amine-reactive.
The co-immunoprecipitation was performed according
to the manufacturer’s instructions followed by a western
blot using corresponding antibodies of interest.
Immunocyto−/−histofluorescence confocal laser scanning
microscopy
Tissue sections or cells were fixed with ice-cold metha-
nol and permeabilized with 1% Triton-X 100 in PBS.
Thereafter, the detergent was removed by repeated
washing in PBS. Primary antibodies (see Additional file 1)
were applied in PBS overnight (4 °C). After the incubation
with secondary antibodies (see Additional file 1) and
subsequent staining with DAPI, cells were covered with
IMMU-MOUNT (Thermo Electron Corporation; Pittsburgh;
USA) and a glass coverslip. Images were taken by confocal
laser scanning microscopy (Nikon Eclipse Ti-E, Düsseldorf,
Germany).
Reverse transcription and quantitative polymerase chain
reaction
Total RNA was extracted from human U937 MФ using
PeqGold TRIFast™ from Peqlab (Erlangen, Germany).
DNase I (RNase-free; Thermo Scientific) was used ac-
cording to the manufacturer’s instructions. The Affinity-
Script Multiple Temperature Reverse Transcriptase and
the Brilliant III Ultra-Fast SYBR® Green Master Mix
were obtained from Agilent Technologies (Waldbronn,
Germany). The QuantiTect Primer Assays were pur-
chased from QIAGEN GmbH (Hilden, Germany) (see
Additional file 2). RNA concentration and purity were
determined by absorbance measurements at 260 nm and
280 nm (A260/A280 = 1.7–2.0) using a NanoDrop 8000
Spectrophotometer (Thermo Scientific, Schwerte,
Germany). Total RNA integrity was confirmed by lab-
on-a-chip technology, using an RNA 6000 NanoChip kit
on an Agilent 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, Germany). On average, we obtained a
RNA Integrity Number (RIN) of 9.71 ± 0.03 (SEM).
1 μg of template RNA was used for cDNA synthesis;
RNA was reverse transcribed using Oligo(dT)12–18
primer and the AffinityScript™ Multiple Temperature
Reverse Transcriptase, according to the manufacturer’s
instructions. The cDNA (diluted 1:20) was amplified
using the Brilliant III Ultra-Fast SYBR® Green QRT-
PCR Master Mix (Stratagene-Agilent Technologies,
Waldbronn, Germany). Amplification and data ana-
lyses were performed using the Mx3005P™ QPCR
System (Stratagene). The data were analyzed using
the relative standard curve method. The NormFinder
software program was used to ascertain the most suit-
able reference gene to normalize the RNA input as
described earlier [27].
Statistical analyses
Statistical analyses were performed using SigmaPlot 12
(Systat Software Inc., USA). After testing for normality (by
Shapiro-Wilk), the unpaired Student’s t-test or one-way
analysis of variance (ANOVA) was used. Data are reported
as mean ± standard error of the mean (SEM). P < 0.05 was
considered as statistically significant.
Results
Localization of JAB1 in CD68+ MΦ in atherosclerotic
plaques of hypercholesterolemic ApoE−/− mice
Our immunohistochemical investigations showed that
JAB1-ir cells localize in atherosclerotic lesions of
ApoE−/− mice after 20 weeks of CED (Fig. 1). JAB1-ir
cells (Fig. 1a, b) and CD68-ir MФ (Fig. 1c, d) were
found predominantly in shoulder and deeper regions
of the plaque, but not in non-atherosclerotic vessel
wall segments e.g. of the brachiocephalic trunk. In
detail, double immunostaining procedures revealed a
co-localization of JAB1- and CD68-immunoreactivity
in MФ in deeper regions of the plaque (Fig. 1e, f ).
However, not all CD68-ir MФ were positive for JAB1-ir
(Fig. 1e, f ).
OxLDL influenced JAB1 protein expression and foam cell
formation in differentiated human MΦ
MФ-derived foam cell formation is a hallmark of athero-
sclerosis. Since our immunohistochemical stainings of
the brachiocephalic trunk of ApoE−/− mice revealed a
co-localization of JAB1-ir and CD68-ir MФ (Fig. 1e, f ),
we investigated the effect of oxLDL in PMA-
differentiated human U937 MΦ on JAB1 protein expres-
sion and foam cell formation in vitro. We showed that
oxLDL (50 μg/ml, 100 μg/ml, 200 μg/ml) exposition
(4 h) induced foam cell formation as indicated by an in-
creased inclusion of lipid droplets in the cytosol and the
perinuclear area (see Additional file 3). LPS treatment
that was performed as positive control for inflammation did
not result in foam cell formation (see Additional file 3).
However, the viability of human U937 MФ was unchanged
after LPS or oxLDL exposition in comparison to the control
(see Additional file 3). We next investigated, whether oxLDL
influences the expression of JAB1 in differentiated human
U937 MФ. We found that the protein level of JAB1 signifi-
cantly and concentration-dependently increased after 4 h
oxLDL exposition (50 μg/ml: 1.39 + 0.15-fold; 100 μg/ml:
1.80 + 0.26-fold; 200 μg/ml: 2.05 + 0.30-fold; p < 0.05) in
comparison with the control (Fig. 2).
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JAB1 silencing attenuated the oxLDL-induced expression
and secretion of TNF-α and IL-6 without influencing the
cellular cholesterol
Our finding that oxLDL induces foam cell formation
with increased JAB1 protein expression suggests a func-
tional effect of JAB1 in MФ after oxLDL exposition.
Next, we transiently silenced JAB1 expression in U937
MФ (siJAB1-MФ). Microscopic investigations revealed
no morphological differences among non-transfected
MФ (medium), nsiJAB1-MФ or siJAB1-MФ (see
Additional file 4a-c). As negative control, we used a
non-silencing siRNA (nsiJAB1-MФ) without homology
to any known mammalian gene. The cell death control
siRNA showed the efficient transfection of siRNA by cell
death (see Additional file 4d). The transient transfection
achieved a significant (p < 0.005) knock-down of JAB1
mRNA 61% or protein 60% compared to non-
transfected MФ (Fig. 3a, b). After oxLDL exposition
(4 h) the JAB1 expression showed no significant differ-
ence on the mRNA as well on the protein level in
comparison to control in siJAB1-MФ (Fig. 3).
In order to test whether JAB1 plays a role during
oxLDL uptake and intracellular cholesterol concentra-
tion, we measured the cholesterol content of siJAB1-MФ
versus non-transfected MФ and nsiJAB1-MФ (Fig. 4).
We examined the effect of JAB1 silencing on TC, FC and
CE accumulation. At first, we show a significant (p <
0.05) increase of TC in non-transfected MФ (1.8-fold),
nsiJAB1-MФ (1.2-fold) and siJAB1-MФ (2.3-fold) after
oxLDL exposition in comparison with corresponding
control MФ (Fig. 4a). Furthermore, FC and CE were in-
creased in non-transfected MФ (FC: 1.7-fold p < 0.05;
CE: 2.9-fold p < 0.05), nsiJAB1-MФ (FC: 1.1-fold; CE:
2.6-fold) and siJAB1-MФ (FC: 2.3-fold; p = 0.05; CE: 2.3-
fold) after 4 h oxLDL exposition in comparison with cor-
responding control MФ (Fig. 4b, c). In summary, JAB1
silencing had no significant effects on TC, FC and CE
Fig. 1 Localization of JAB1 in CD68+ MΦ in atherosclerotic plaques of
hypercholesterolemic ApoE−/− mice. Representative cross-sections of the
brachiocephalic trunk of ApoE−/− mice at 30 weeks of age are shown. In
an atherosclerotic plaque of ApoE−/− mice JAB1-immunoreactivity (a, b)
was localized in CD68+ MΦ (c, d), as seen in merge (e, f) labelled by *.
JAB1- and CD68-immunoreactivity was detected by confocal laser
scanning microscopy (Nikon Eclipse) and analyzed with Fiji ImageJ
software. Nuclei were counterstained with DAPI (blue). Representative
photos from 4 independent experiments are shown. Bars: 50 μm
Fig. 2 OxLDL influence JAB1 protein expression and foam cell formation in differentiated human MΦ. PMA-differentiated human U937 MΦ were
incubated (4 h) with medium alone (= control) or oxLDL (50, 100, 200 μg/ml). The JAB1 and α-tubulin protein levels were determined using western
blot analysis and quantified by ImageJ. Expression was normalized against α-tubulin. Bars represent mean ± SEM of 4 independent experiments.
*p < 0.05 significance vs. control
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accumulation after oxLDL exposition in comparison
with non-transfected MΦ or nsiJAB1-MΦ.
Since oxLDL induces production and release of pro-
inflammatory cytokines, we examined the effect of JAB1
silencing on expression and secretion of TNF-α and IL-
6. Here we observed a significant increase of mRNA ex-
pression (2.58-fold TNF-α, 12.15-fold IL-6) and protein
secretion (67.74 pg/ml TNF-α, 1.7 ng/ml IL-6) after
oxLDL exposition (4 h) in non-transfected MΦ (Fig. 5).
In addition, after oxLDL exposition (4 h), nsiJAB1-MΦ
showed a significant increase of mRNA expression
(2.29-fold TNF-α, 10.53-fold IL-6) and protein secretion
(80.35 pg/ml TNF-α, 6.39 ng/ml IL-6) in comparison
with nsiJAB1-MΦ without oxLDL exposition (Fig. 5).
Furthermore, JAB1 silencing resulted in a significant (p
< 0.005) decrease of TNF-α and IL-6 mRNA expression
(31% TNF-α; 18% IL-6) in comparison to nsiJAB1-MФ
(as well as non-transfected MΦ) after oxLDL treatment
(4 h) (Fig. 5a, b). Moreover, JAB1 silencing also resulted
in a significant (p < 0.05) inhibition of TNF-α and IL-6
Fig. 3 Knock-down of JAB1 mRNA and protein level in human MФ.
PMA-differentiated human U937 MΦ were transfected with siRNA
JAB1 (siJAB1-MФ) or negative siRNA (nsiJAB1-MФ) for 48 h. Non-
transfected MФ, nsiJAB1-MФ and siJAB1- MФ were treated with or
without (control) oxLDL (50 μg/ml) for 4 h. a The JAB1 mRNA
expression levels were determined using RT-qPCR. Bars represent
mean ± SEM of 3 independent experiments. *p < 0.05 significance vs.
non-transfected MФ or nsiJAB1-MФ. b The JAB1 and α-tubulin
protein levels were determined using western blot analysis and
quantified by ImageJ. Expression was normalized against α-tubulin.
Bars represent mean ± SEM of 5 independent experiments. [m] –
non-transfected MФ, [si] - siJAB1-MФ, [nsi] – nsiJAB1-MФ; *p < 0.05
significance vs. non-transfected MФ or nsiJAB1-MФ, #p < 0.05
significance vs. control
Fig. 4 TC, FC and CE contents in non-transfected, siJAB1- or nsiJAB1-
U937 MФ. Cells (1*106 cells/well) were cultured in the presence of
PMA (20nM) for 24 h and transfected with siRNA JAB1 (siJAB1-MФ)
or negative siRNA (nsiJAB1-MФ) for 48 h. Non-transfected MФ, nsi-
JAB1-MФ or siJAB1- MФ were incubated (4 h) with oxLDL (50 μg/ml) or
without (control). a TC, total cholesterol, (b) FC, free cholesterol and (c) EC,
esterified cholesterol, were normalized to total protein. Data are expressed
as mean+ SEM of 4 independent experiments. *p< 0.05 significance vs.
corresponding control
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secretion (72% TNF-α; 29% IL-6) in comparison with
nsiJAB1-MФ after oxLDL treatment (4 h) (Fig. 5c, d).
OxLDL induced JAB1 expression by NF-κB-independent
signaling in human MФ
After our demonstration that oxLDL leads to the expres-
sion of inflammatory molecules in dependence of JAB1
expression, we examined whether the oxLDL-induced
expression of JAB1 influences pivotal proteins of the
NF-κB signal transduction pathway, like Iκ-Bα.
We found that Iκ-Bα was significantly (p < 0.005) 2.17
± 0.24-fold increased on the protein level after oxLDL
treatment (4 h) of differentiated human U937 MΦ
(Fig. 6a). Also, there were no statistically significant
differences in NF-κB p65 protein quantity (Fig. 6b) or
nuclear translocation, as shown by western blot (Fig. 6c).
As positive control for inflammation, LPS treatment
(4 h) significantly (p < 0.005) increased the Iκ-Bα protein
expression (2.13 ± 0.15-fold), but no statistically signifi-
cant translocation of NF-kB p65 into the nucleus could
be substantiated after LPS treatment for 4 h (Fig. 6c).
In addition, we tested for potential the interaction of
JAB1 with IKKß, Iκ-Bα and NF-κB in untreated or
oxLDL-treated human MΦ by co-immunoprecipitation
(Fig. 6d). We clarified the cell lysate by using the Con-
trol Agarose Resin in order to reduce to reduce non-
specific protein binding (PreClear cell lysate) (Fig. 6d).
In the resulting eluate we detected neither JAB1 nor
IKKß, Iκ-Bα and NF-κB p65 protein, implicating that the
performed immunoprecipitation was specific for the
antibody against JAB1 (Fig. 6d). However, the co-
immunoprecipitation showed no interaction of JAB1
with IKKß, Iκ-Bα and NF-κB p65 (Fig. 6d).
OxLDL-induced phosphorylation of p38 MAPK and
interaction with JAB1 in vitro in human MΦ and in
arteriosclerotic plaques
The targets of the NF-kB and p38 MAPK signaling
pathway are transcription factors that influence pro-
inflammatory cytokines like IL-6 and TNF-α. We
showed that independent from NF-kB signaling the
TNF-α and IL-6 mRNA expression and protein secretion
were significantly increased in oxLDL-treated MΦ in
comparison to control MΦ. Therefore, we investigated
the activation of p38 MAPK marked by the phosphoryl-
ation of Thr180 and Tyr182. LPS- or oxLDL-treatment
(4 h) of differentiated human U937 MΦ induced the ac-
tivation of p38 MAPK as indicated by a significantly
Fig. 5 JAB1 silencing attenuates the oxLDL-induced expression and secretion of TNF-α and IL-6. PMA-differentiated human U937 MΦ were treated
(4 h) with 50 μg/ml oxLDL and compared to the control (medium). TNF-α (a) and IL-6 (c) mRNA expression levels were determined using RT-qPCR.
TNF-α (b) and IL-6 (d) protein secretion was determined using ELISA. Bars represent mean ± SEM of 3 independent experiments. *p < 0.05 significance
vs. control, #p < 0.05 significance vs. non-transfected MФ or nsiJAB1-MФ
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increased protein expression (37% ± 11% or 62% ± 17%;
p < 0.05) of phosphorylated p38 MAPK (Fig. 7a). In
addition, we analyzed the co-localization and interaction
of JAB1 with p38 MAPK in vivo and in vitro. Our immu-
nohistochemical investigations showed that p38 MAPK-
ir cells were predominantly localized in shoulder and
middle regions of atherosclerotic plaques of ApoE−/−
mice (Fig. 7b-d). Additionally, using double immuno-
fluorescence technique, p38 MAPK-ir was partly co-
localized and regionally not co-localized with JAB1-ir in
the shoulder region of the plaque (Fig. 7b-d). We found
JAB1 co-localized with p38 MAPK in the cytosol or not
co-localized with p38 MAPK on the cell surface/in the
cell membrane in an atherosclerotic plaque of ApoE−/−
mice (Fig. 7b, d).
Furthermore, we analyzed the co-localization and inter-
action of JAB1 with p38 MAPK without oxLDL and after
oxLDL treatment using immunofluorescence confocal laser
scanning microscopy (Fig. 7e-l) or co-immunoprecipitation
(Fig. 7m). We found an interaction of JAB1 with p38 MAPK
in untreated (= negative control) human MΦ, but fewer
after 4 h oxLDL exposition (Fig. 7i-m). In the eluate of the
Control Agarose Resin (negative control), we detected nei-
ther JAB1 nor p38 MAPK protein, indicating successful im-
munoprecipitation specific for the antibody against JAB1
(Fig. 7m). Quantification of co-immunoprecipitated (CO-IP)
JAB1 by Western Blot analysis in the eluate revealed a sig-
nificant increase (20%; p= 0.02 vs. control) of JAB1-protein
level in comparison with the control (data not shown).
Using confocal laser scanning microscopy, we found that in
Fig. 6 OxLDL-induced JAB1 and NF-κB signaling in human MФ. PMA-differentiated human U937 MΦ were treated (4 h) with or without 50 μg/ml
oxLDL or 0.1 μg/ml LPS. The protein expression level of (a) Iκ-Bα and (b) NF-κB p65 were determined using western blot analysis and quantified by ImageJ.
Expression was normalized against α-tubulin. Bars represent mean± SEM of 6 (a) or 3 (b) independent experiments. *p< 0.005 significance vs. control. c
Cytosolic protein [C] and nuclear protein [N] were extracted and western blot analysis was performed for the NF-κB p65 subunit and quantified by ImageJ
(Bars represent mean+ SEM of 5 independent experiments). d Immunoprecipitation of JAB1 was carried out with anti-JAB1 [2A10.8] (GenTex) antibodies
followed by immunoblot detection for JAB1/COPS5, IKKß, Iκ-Bα and NF-κB in PreClear cell lysates and immunoprecipitates (IP). The eluate from Control
Agarose Resin served as negative control. The depicted blot is representative for 3 independent experiments
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untreated (=negative control) MΦ JAB1 immunofluores-
cence was detected mainly in the cytosol (Fig. 7f). After
oxLDL treatment, however, JAB1 immunofluorescence was
located on the cell surface/in the cell membrane (Fig. 7j).
Moreover, p38 MAPK was found in the cytosol and in the
nucleus of untreated and oxLDL-treated human MΦ
(Fig. 7g, k). Furthermore, JAB1 and p38 MAPK
immunofluorescence signals were co-localized in the cytosol
in control, but not in oxLDL-treated human MΦ (Fig. 7h, l).
Discussion
Blood cholesterol and particularly LDL cholesterol, espe-
cially oxLDL, plays a key role in all stages of atheroscler-
osis by regulating the expression of adhesion molecules,
Fig. 7 OxLDL-induced phosphorylation of p38 MAPK and interaction with JAB1 in vitro in human MΦ and in arteriosclerotic plaques. a The protein
levels of p38 MAPK and P-p38 (Thr180, Try182) were determined by western blot analysis after treatment (4 h) of PMA-differentiated human U937 MΦ
with or without 50 μg/ml oxLDL or 0.1 μg/ml LPS. Expression was normalized against α-tubulin. Bars represent mean ± SEM of 4 independent
experiments (*p < 0.05). b–d Representative cross-sections of the brachiocephalic trunk of ApoE−/− mice at 30 weeks of age. JAB1 (b) is co-localized
(broken arrow) and not co-localized (white arrow) with p38 MAPK (c) in atherosclerotic plaque, as seen in merge (d). JAB1 was detected on the cell sur-
face/cell membrane (*) or in the cytosol (#) in atherosclerotic plaque (b, d). Immunofluorescent staining of JAB1 and p38 MAPK was observed by con-
focal microscopy (Nikon Eclipse) and analyzed with Fiji ImageJ. The individual channels are depicted in columns: blue, DNA; red, JAB1/COPS5; green,
p38 MAPK. Representative photos from 4 independent experiments with similar results are shown. Bars: 50 μm (b, c, d). e–l Immunofluorescence of
JAB1 (f, j) and p38 MAPK (g, k) in PMA-differentiated human U937 MΦ was observed by confocal laser scanning microscopy (Nikon Eclipse) and ana-
lyzed with Fiji ImageJ. The individual channels are depicted in columns: blue, DNA; green, JAB1/COPS5; red, p38 MAPK. (h, l) The white cross represents
the intersection of x-, y- and z-axis in the orthogonal coordinate system. Representative immunofluorescence results from 3 independent experiments
are shown. Scale bars: 10 μm. m Immunoprecipitation (IP) of JAB1 was carried out with anti-JAB1 [2A10.8] (GenTex) antibodies followed by
immunoblot detection for JAB1 and p38 MAPK in PreClear cell lysates. The eluate from Control Agarose Resin served as negative control. The blot is
representative for 4 independent experiments
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chemokines and pro-inflammatory cytokines. Moreover,
oxLDL triggers processes mediated by various signaling
pathways in different cell types, such as recruitment of
mononuclear cells, lipid accumulation in MΦ (foam cell
formation) as well as inflammatory and cytotoxic re-
sponses [28, 29]. Additionally, oxLDL plays a central role
in the genesis of vulnerable plaques and plaque instabil-
ity in human coronary arteries with lesions due to abun-
dant foam cell formation [30].
Here we showed a localization of JAB1 in CD68+ MΦ
in atherosclerotic lesions of the brachiocephalic trunk of
hypercholesterolemic ApoE−/− mice (after 20 weeks
CED). In non-atherosclerotic/plaque-free arteries JAB1-
ir was not observed. These data indicate an important
role of JAB1 during foam cell formation and consecutive
atherosclerotic plaque development and progression.
Our data of CD68-ir MΦ in atherosclerotic lesions are
in accordance with other reports describing JAB1 posi-
tive CD68-ir MΦ in human aortic fatty streak lesions
[11]. Moreover, it has been described that different
stages of human atherosclerosis contain different
amounts of foam cells, associated with JAB1 expression
[11] and athero-progression [3]. For this reason, our data
and those of others suggest that JAB1 is involved in the
ubiquitin-proteasome degradation machinery [16] and
participates in the regulation of signal transduction
pathways [10, 20] concerning oxLDL internalization/
metabolization.
Based on the co-localization of JAB1- and CD68+-ir in
MΦ of atherosclerotic lesions, e.g. of the brachiocephalic
trunk of ApoE−/− mice, we examined the effect of oxLDL
on foam cell formation in vitro and the role of JAB1 in
this process, which is still unclear. Here we showed that
treatment of differentiated human MΦ with oxLDL re-
sulted in foam cell formation in vitro with a significant
and characteristic intracellular storage of lipid-droplets,
as well as a significant increased content of TC, FC and
EC. In contrast, treatment with LPS, as a positive control
for inflammation, did not lead to foam cell formation.
These data are in accordance with others using human
U937 MΦ [31, 32] or murine RAW 264.7 [7]. Moreover,
we found a significant increase of JAB1 protein expres-
sion of more than 50% in human foam cells after oxLDL
incubation - and to a lower percentage (~30%; not sig-
nificant) also after LPS treatment. These data indicate
that oxLDL induces JAB1 expression in vivo and in vitro.
However, JAB1 does not directly regulate the cellular
cholesterol content in human MФ, as demonstrated e. g.
by our JAB1-siRNA experiments. Therefore, this regula-
tion may be due to COP9, containing JAB1 as a subunit,
that controls the ubiquitinylation of ATP-binding cas-
sette protein A1 (ABCA1), which mediates the transfer
of cellular free cholesterol and phospholipids to apolipo-
protein A-1 (apoA-1) [33].
Given that oxLDL plays a key role in all stages of ath-
erosclerosis by regulating the expression of JAB1 and
pro-inflammatory cytokines, we showed an oxLDL-
induced upregulation of TNF-α and IL-6 mRNA expres-
sion and protein secretion in differentiated human MФ.
Vice versa, JAB1 silencing (up to 60% on mRNA expres-
sion and protein level in oxLDL stimulated human MФ)
resulted in a significant decrease of TNF-α and IL-6
mRNA expression and protein secretion after oxLDL
treatment in comparison to nsiJAB1-MФ. These data in-
dicate that the oxLDL-induced expression and secretion
of these two pro-inflammatory cytokines depend on
JAB1 expression in human MФ. Furthermore, it has
been reported most recently that the genetic inhibition
of JAB1 using knock-down gene expression abrogated
the binding of the inhibitory Iκ-Bα subunit to NF-κB
and enhanced TNF-α production in EC, while JAB1
overexpression had the opposite effect, suggesting a cru-
cial role of JAB1 after TNF-α stimulation [10]. However,
our study cannot confirm these findings in oxLDL
treated human MФ, possibly due to different cell types
and/or different treatment.
Moreover, we tested the effects of oxLDL on Ik-Bα
and NF-κB p65 expression in differentiated human MΦ,
since the ubiquitination machinery necessary to activate
the NF-kB p65 might be regulated by the COP9 signalo-
some [10, 18]. Our present data demonstrate that oxLDL
treatment of differentiated human MΦ resulted in an in-
creased Iκ-Bα protein level. Additionally, we observed
no significant nuclear translocation of NF-κB p65 after
4 h incubation of human MΦ with oxLDL. However, the
NF-ĸB p65 nuclear translocation seems to be time-
dependent after oxLDL or LPS stimulation of human
MФ, because we and others found a NF-ĸB p65 nuclear
translocation after 24 h oxLDL or LPS treatment (see
Additional file 5) [34]. Therefore, it seems that JAB1
does not influence the NF-kB p65 signaling after 4 h
oxLDL treatment in differentiated human MΦ.
Furthermore, the p38 pathway is implicated in choles-
terol ester accumulation in MΦ and the development of
atherosclerosis [35], since its activation plays an essential
role in the production of inflammatory cytokines (TNF-
α, IL-6) [36]. It has already been demonstrated that
JAB1 is critically involved in TLR-mediated activation of
p38 MAPK and ERK in mouse MФ [20]. We here show
that JAB1 is an important factor for p38 MAPK medi-
ated inflammation, however obviously independent from
NF-kB in human MФ after oxLDL treatment. Therefore,
future studies are necessary to prove the molecular
mechanism of JAB1 and p38 MAPK in oxLDL treated
MФ. In our experiments, stimulation of differentiated
human MΦ with oxLDL led to significant increases of
the phosphorylated p38 (P-p38) and mRNA expression
of the pro-inflammatory cytokines TNF-α and IL-6,
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accompanied by an increase of the intracellular lipid
accumulation. Previous studies with murine RAW264.7
MΦ showed that the inhibition of p38 MAPK with
curcuma, a naturally occurring yellow pigment from the
rhizomes of the plant Curcuma longa L., leads to the
inhibition of oxLDL-induced foam cell formation and of
CD36 expression [7]. Our results extend the importance
of p38 MAPK activation during oxLDL-induced foam cell
formation in human MФ and for the production of pro-
inflammatory mediators such TNF-α and IL-6 [37, 38] im-
plicating a major role during atherosclerotic processes.
Furthermore, we identified the relationship between the
oxLDL-induced p38 activation, increase of JAB1 protein
level and foam cell formation. In addition, we showed a
loss of co-localization and interaction of JAB1 with p38
MAPK by confocal laser scanning immunofluorescence
technique and co-immunoprecipitation after 4 h oxLDL
treatment. We showed in vivo that JAB1 was not co-
localized with p38 MAPK and localized on the cell sur-
face/in the cell membrane in some parts within the shoul-
der regions of atherosclerotic lesions of ApoE−/− mice,
indicating possible inflammatory processes in areas prone
to rupture. In addition, we observed a translocation of
JAB1 from the cytosol to the cell membrane in U937 MФ
after 4 h oxLDL treatment. Particularly in this context, we
identified that oxLDL treatment leads to p38 MAPK
activation through phosphorylation at the sites Thr180
and Try182 by the elimination of JAB1 from p38 MAPK.
The activation of p38 MAPK signaling pathway leads to
increase expression of cytokines (TNF-a, IL-6) and JAB1
protein. The JAB1 silencing resulted in decrease of cyto-
kine expression and secretion. JAB1 up-regulates the in-
nate immune response by activation of MAPK-mediates
pathway. On the other side, our data corroborate the
hypothesis that JAB1 is regulated by MAPK-mediates
pathway. However, another study showed that JAB1 dele-
tion significantly attenuates the induction of phosphory-
lated p38 and ERK upon TLR ligand stimulation in bone
marrow-derived mouse MΦ [20]. This attenuation is
specific for p38 MAPK and ERK without affecting activa-
tion of NF-ĸB, and related to a possible inflammatory role
of JAB1 [20]. Further research is needed to understand
why JAB1 silencing leads to prevention of inflammation
and also what are the functional background of the inter-
action of JAB1 and p38 MAPK in human MФ.
The recent data indicate that JAB1 is critically involved
in the oxLDL-induced inflammatory signaling pathway
and cytokine secretion (TNF-α, IL-6), with potential
consequences for atherosclerotic plaque progression and
plaque rupture.
Conclusion
In summary, we showed that JAB1, which can be stimu-
lated by LPS or oxLDL, acts as a mediator between
different inflammatory signaling pathways in MΦ during
oxLDL exposition, without influencing the foam cell
formation under our experimental conditions. Further
investigations are required to understand the impact of
oxLDL and p38 MAPK on JAB1 regulation, cellular
localization and the pivotal participation in plaque progres-
sion. In this context, our data provide plausible evidence to
consider the JAB1 subunit of COP9 as a possible target for
the treatment of diseases associated with chronic inflamma-
tion and particularly with atherosclerosis.
Additional files
Additional file 1: Antibodies used in this study. (PDF 146 kb)
Additional file 2: Primers used in this study. (PDF 134 kb)
Additional file 3: Figure S1. OxLDL influence JAB1 protein expression
and foam cell formation in differentiated human MΦ. (PDF 258 kb)
Additional file 4: Knock-down of JAB1 in human MФ. (PDF 264 kb)
Additional file 5: OxLDL-induced NF-κB signaling in human MФ after
24 h. (PDF 340 kb)
Abbreviations
ABCA1: ATP-binding cassette protein A1; ANOVA: Analysis of variance; apoA-
1: Apolipoprotein A-1; apoE: Apolipoprotein E; BCA: Bicinchoninic acid; CCL2: C-C
motif chemokine ligand 2; CE: Cholesteryl ester; CED: Cholesterol-enriched diet;
COP9: Constitutive photomorphogenesis 9; CRL: Cullin-RING ubiquitin ligase;
CSN5: COP9 signalosome complex unit 5; FC: Free cholesterol; HUVEC: Human
umbilical vein endothelial cells; ICAM-1: Intercellular adhesion molecule 1; IKKß: IkB
kinase ß; IL-6: Interleukin 6; ir: Immunoreactive; Iκ-Bα: Nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor, alpha; JAB1: Jun activation domain
binding protein-1; JAMM: JAB1/MPN domain metalloenzyme;
LPS: Lipopolysaccharide; MAPK: Mitogen-activated protein kinase; MK2: MAPK-
activated protein kinase-2; MPN: Mpr/Pad1/N-terminal; MΦ: Macrophages; NF-
κB: Nuclear factor-kappa B; nsiJAB1: Negative control siJAB1; OD: Optical density;
ORO: Oil red O; oxLDL: Oxidized low-density lipoprotein; PBS: Phosphate buffered
saline; PMA: Phorbol 12-mystriate 13-acetate; RIPA: Radio-immunoprecipitation
assay; SCF: Skp1, Cullins, F-box proteins; SEM: Standard error of the mean;
siJAB1: siRNA JAB1; TBS: Tris buffered saline; TC: Total cholesterol; TNF-α: Tumor
necrosis factor-alpha; UPS: Ubiquitin proteasome system; VCAM-1: Vascular cell
adhesion molecule 1
Acknowledgments
We thank Mirjam Bertoune for read and approved the final manuscript.




Availability of data and materials
Not applicable.
Authors’ contributions
AS conceived the study, AS and GAB are responsible for the design of the
research; AS performed the experiments; AS and HS participated in the
histological analysis. AS, GAB and RK analyzed the data and interpreted
the results of the experiments; AS prepared the figures and drafted the
manuscript; RK and GAB edited and revised the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Schwarz et al. Journal of Biomedical Science  (2017) 24:12 Page 11 of 12
Consent for publication
We accept the conditions of submission and the BioMed Central Copyright
and License Agreement.
Ethics approval
Our study doesn’t include any data about people or human tissue samples.
All animal experiments in this research were reviewed and approved by the
Regierungspräsidium Karlsruhe and the local authorities at the University of
Heidelberg (Az 35–9185.81/g-99/06).
Received: 26 August 2016 Accepted: 31 January 2017
References
1. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):
115–26.
2. Vindis C. Autophagy: an emerging therapeutic target in vascular diseases.
Br J Pharmacol. 2015;172(9):2167–78. doi:10.1111/bph.13052.
3. Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis.
Clin Chim Acta. 2013;424:245–52. doi:10.1016/j.cca.2013.06.006.
4. Jovinge S, Ares MP, Kallin B, Nilsson J. Human monocytes/macrophages
release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol.
1996;16(12):1573–9.
5. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of
NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–63. doi:10.1146/
annurev.immunol.18.1.621.
6. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappa B controls expression
of inhibitor I kappa B alpha: evidence for an inducible autoregulatory
pathway. Science. 1993;259(5103):1912–5.
7. Min KJ, Um HJ, Cho KH, Kwon TK. Curcumin inhibits oxLDL-induced CD36
expression and foam cell formation through the inhibition of p38 MAPK
phosphorylation. Food Chem Toxicol. 2013;58:77–85. doi:10.1016/j.fct.2013.
04.008.
8. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, et al.
MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis.
Nat Cell Biol. 1999;1(2):94–7. doi:10.1038/10061.
9. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB. MAPKAP kinase
2-deficient mice are resistant to collagen-induced arthritis. J Immunol.
2006;177(3):1913–7.
10. Asare Y, Shagdarsuren E, Schmid J, Tilstam PV, Grommes J, El Bounkari O, et al.
Endothelial CSN5 impairs NF-kappaB activation and monocyte adhesion to
endothelial cells and is highly expressed in human atherosclerotic
lesions. Thromb Haemost. 2013;110(1):1.
11. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler
S, et al. Expression of macrophage migration inhibitory factor in different
stages of human atherosclerosis. Circulation. 2002;105(13):1561–6.
12. Burger-Kentischer A, Finkelmeier D, Thiele M, Schmucker J, Geiger G, Tovar GE,
et al. Binding of JAB1/CSN5 to MIF is mediated by the MPN domain but is
independent of the JAMM motif. FEBS Lett. 2005;579(7):1693–701.
13. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase
inhibitor p27Kip1 is instigated by Jab1. Nature. 1999;398(6723):160–5.
14. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, et al.
COP9 signalosome-specific phosphorylation targets p53 to degradation by
the ubiquitin system. Embo J. 2001;20(7):1630–9.
15. Berse M, Bounpheng M, Huang X, Christy B, Pollmann C, Dubiel W.
Ubiquitin-dependent degradation of Id1 and Id3 is mediated by the COP9
signalosome. J Mol Biol. 2004;343(2):361–70.
16. Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex
situation. EMBO Rep. 2001;2(2):96–101.
17. Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, et al.
Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8
from Cul1. Science. 2002;298(5593):608–11.
18. Schweitzer K, Bozko PM, Dubiel W, Naumann M. CSN controls NF-kappaB by
deubiquitinylation of IkappaBalpha. Embo J. 2007;26(6):1532–41.
19. Wei N, Serino G, Deng XW. The COP9 signalosome: more than a protease.
Trends Biochem Sci. 2008;33(12):592–600. doi:10.1016/j.tibs.2008.09.004.
20. Deng Z, Pardi R, Cheadle W, Xiang X, Zhang S, Shah SV, et al. Plant
homologue constitutive photomorphogenesis 9 (COP9) signalosome
subunit CSN5 regulates innate immune responses in macrophages. Blood.
2011;117(18):4796–804.
21. Bonaterra GA, Zugel S, Thogersen J, Walter SA, Haberkorn U, Strelau J, et al.
Growth differentiation factor-15 deficiency inhibits atherosclerosis progression
by regulating interleukin-6-dependent inflammatory response to vascular
injury. J Am Heart Assoc. 2012;1(6):e002550. doi:10.1161/JAHA.112.002550.
22. Pike MC, Fischer DG, Koren HS, Snyderman R. Development of specific
receptors for N-formylated chemotactic peptides in a human monocyte cell
line stimulated with lymphokines. J Exp Med. 1980;152(1):31–40.
23. Schlesinger JJ, Brandriss MW. Antibody-mediated infection of macrophages
and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol.
1981;8(2):103–17.
24. Galle J, Wanner C. Oxidized LDL and Lp(a). Preparation, modification, and
analysis. Methods Mol Biol. 1998;108:119–30. doi:10.1385/0-89603-472-0:119.
25. Steinbrecher UP. Oxidation of human low density lipoprotein results in
derivatization of lysine residues of apolipoprotein B by lipid peroxide
decomposition products. J Biol Chem. 1987;262(8):3603–8.
26. Boncler M, Rozalski M, Krajewska U, Podsedek A, Watala C. Comparison of
PrestoBlue and MTT assays of cellular viability in the assessment of anti-
proliferative effects of plant extracts on human endothelial cells. J
Pharmacol Toxicol Methods. 2014;69(1):9–16. doi:10.1016/j.vascn.2013.09.003.
27. Stern-Straeter J, Bonaterra GA, Hormann K, Kinscherf R, Goessler UR.
Identification of valid reference genes during the differentiation of human
myoblasts. BMC Mol Biol. 2009;10:66. doi:10.1186/1471-2199-10-66.
28. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells
alter low density lipoprotein in vitro by free radical oxidation.
Arteriosclerosis. 1984;4(4):357–64.
29. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in
atherogenesis. J Clin Invest. 1991;88(6):1785–92. doi:10.1172/JCI115499.
30. Ehara S, Ueda M, Naruko T, Haze K, Matsuo T, Ogami M, et al.
Pathophysiological role of oxidized low-density lipoprotein in plaque instability
in coronary artery diseases. J Diabetes Complications. 2002;16(1):60–4.
31. Jiang G, Li T, Qiu Y, Rui Y, Chen W, Lou Y. RNA interference for HIF-1alpha
inhibits foam cells formation in vitro. Eur J Pharmacol. 2007;562(3):183–90.
32. Huang ZG, Liang C, Han SF, Wu ZG. Vitamin E ameliorates ox-LDL-induced
foam cells formation through modulating the activities of oxidative
stress-induced NF-kappaB pathway. Mol Cell Biochem. 2012;363(1–2):11–9.
doi:10.1007/s11010-011-1153-2.
33. Azuma Y, Takada M, Maeda M, Kioka N, Ueda K. The COP9 signalosome
controls ubiquitinylation of ABCA1. Biochem Biophys Res Commun. 2009;
382(1):145–8.
34. Wang Y, Wang X, Sun M, Zhang Z, Cao H, Chen X. NF-kB activity-dependent P-
selectin involved in ox-LDL-induced foam cell formation in U937 cell. Biochem
Biophys Res Commun. 2011;411(3):543–8. doi:10.1016/j.bbrc.2011.06.177.
35. Mei S, Gu H, Ward A, Yang X, Guo H, He K, et al. p38 mitogen-activated
protein kinase (MAPK) promotes cholesterol ester accumulation in
macrophages through inhibition of macroautophagy. J Biol Chem. 2012;
287(15):11761–8. doi:10.1074/jbc.M111.333575.
36. Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR. Induction of
cyclooxygenase-2 by the activated MEKK1 – > SEK1/MKK4 – > p38 mitogen-
activated protein kinase pathway. J Biol Chem. 1998;273(21):12901–8.
37. Garcia J, Lemercier B, Roman-Roman S, Rawadi G. A Mycoplasma fermentans-
derived synthetic lipopeptide induces AP-1 and NF-kappaB activity and
cytokine secretion in macrophages via the activation of mitogen-activated
protein kinase pathways. J Biol Chem. 1998;273(51):34391–8.
38. Yang Y, Kim SC, Yu T, Yi YS, Rhee MH, Sung GH, et al. Functional roles of p38
mitogen-activated protein kinase in macrophage-mediated inflammatory
responses. Mediators Inflamm. 2014;2014:352371. doi:10.1155/2014/352371.
Schwarz et al. Journal of Biomedical Science  (2017) 24:12 Page 12 of 12
